The new St. Jude Medical™ Trifecta™ valve with Glide™ Technology (GT) features several enhancements that make the device implantation easier in patients with challenging anatomies and minimally invasive approaches.
2016, St. Jude Medical launched the company’s Trifecta™ valve with Glide™ Technology (GT) for the treatment of diseased, damaged or malfunctioning aortic heart valves. The new Trifecta™ GT tissue valve is designed to provide physicians with enhanced valve delivery to ease implantation in challenging anatomies, while combining with the proven best-in-class hemodynamic excellence of the Trifecta™ valve.
A major differentiator of this next-generation valve is the soft sewing cuff, which is designed to more easily conform to the patient’s annulus. Another update is a streamlined, conical valve holder designed for better access and visibility. The holder is now a single-cut, quick release holder designed for greater efficiency.
“From a surgeon’s perspective, passing your sutures through the Trifecta GT valve cuff is now easier because the needle glides through; facilitating the surgical implant,” Michael Borger, director of the Cardiovascular Institute and the director, Aortic Surgery, Columbia University Medical Center, New York. “Overall the enhancements to Trifecta GT valve make surgical aortic valve replacement an easier operation for the surgeon to do. Anything in cardiac surgery that simplifies the procedure will always be welcome from the surgeon’s point of view.”
Rooted in Evidence
The original Trifecta valve provided surgeons with a tissue valve designed to function in the same way as their patients’ native aortic valve. The improvements made to the Trifecta GT valve provides a tissue valve option that is easier to implant but that retains the best-in-class haemodynamic performance of the original Trifecta valve.1
In the largest prospective evaluations of surgical aortic valve prosthesis, Bavaria et al2 found that among patients who underwent surgical aortic valve replacement with the Trifecta valve, 83.5 percent were in New York Heart Association (NYHA) class I with no patients in NYHA class IV and 96.1 percent of patients were free from NYHA class III or IV symptoms at two years post-implant. “At one year follow-up, average mean gradients ranged from 10.7mmHg to 4.7mmHg and average peak gradients ranged from 19.9mmHg to 9.2mmHg for valve sizes 19mm to 29mm, respectively,” the authors report.
Concluding, Bavaria et al comment: “The St. Jude Medical™ Trifecta™ valve is a unique pericardial bioprosthesis with design elements that incorporate significant improvements in hemodynamic performance over previous-generation valve while providing ease of implantation.”
Key enhancements with Trifecta™GT valve
• Soft compliant sewing cuff with minimal needle penetration, suture drag and parachuting for smooth valve delivery.
• Additional cuff scallop follows the contour of the annulus.
• Suture markers aid in optimal needle placement and spacing.
• Streamlined conical valve holder for better access and visibility.
• Increased radiopacity for future valve consider
1. Levy, F., Donal, E., Biere, L., Szymanski, C., Remadi, J., Flecher, E., . . . Tribouilloy, C. (2013). Hemodynamic profile changes during exercise of the new St-Jude trifecta aortic bioprosthesis: Results from a French multicentre exercise echocardiographic study. Archives of Cardiovascular Diseases, 106(4), 250
St. Jude Medical UK Ltd
01789 207600 Mainfjeffs@sjm.com Email
Capulet House, Stratford Business & Technology Park,
Banbury Road, Stratford upon Avon